Literature DB >> 7667906

Pathogenesis of porcine circovirus; experimental infections of colostrum deprived piglets and examination of pig foetal material.

G M Allan1, F McNeilly, J P Cassidy, G A Reilly, B Adair, W A Ellis, M S McNulty.   

Abstract

The results of virus and antigen distribution following experimental infection of colostrum deprived pigs with pig circovirus (PCV) by oral/nasal and intravenous routes are reported. PCV and antigen were detected using virus isolation and indirect immunofluorescence on cryostat sections respectively. PCV antigen was detected in tissues throughout the body but primarily in spleen thymus, and lung. No PCV antigen or virus was detected in tissue samples from the central nervous system. Examination of pig foetal material from field cases of abortion/stillbirth resulted in 3 PCV isolates from 2 sera and a spleen sample from 2 groups of stillborn piglets from the same farm. No antibody to PCV alone was detected in 160 foetal sera tested. These results suggest that transplacental infection with PCV does occur, possibly prior to foetal immunocompetance. However, it is probably not a significant cause of reproductive disorders in pigs in Northern Ireland.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667906     DOI: 10.1016/0378-1135(94)00136-k

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  68 in total

1.  Retrospective serological survey of antibodies to porcine circovirus type 1 and type 2.

Authors:  R Magar; P Müller; R Larochelle
Journal:  Can J Vet Res       Date:  2000-07       Impact factor: 1.310

2.  Epitope mapping of the major capsid protein of type 2 porcine circovirus (PCV2) by using chimeric PCV1 and PCV2.

Authors:  Porntippa Lekcharoensuk; Igor Morozov; Prem S Paul; Nattarat Thangthumniyom; Worawidh Wajjawalku; X J Meng
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

3.  Effects of porcine circovirus type 2 (PCV2) maternal antibodies on experimental infection of piglets with PCV2.

Authors:  N E McKeown; T Opriessnig; P Thomas; D K Guenette; F Elvinger; M Fenaux; P G Halbur; X J Meng
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 4.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

5.  Cloned genomic DNA of type 2 porcine circovirus is infectious when injected directly into the liver and lymph nodes of pigs: characterization of clinical disease, virus distribution, and pathologic lesions.

Authors:  M Fenaux; P G Halbur; G Haqshenas; R Royer; P Thomas; P Nawagitgul; M Gill; T E Toth; X J Meng
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Detection and characterization of porcine circovirus associated with postweaning multisystemic wasting syndrome in pigs.

Authors:  G P Nayar; A Hamel; L Lin
Journal:  Can Vet J       Date:  1997-06       Impact factor: 1.008

7.  Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway during porcine circovirus type 2 infection facilitates cell survival and viral replication.

Authors:  Li Wei; Shanshan Zhu; Jing Wang; Jue Liu
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Immunogenicity and pathogenicity of chimeric infectious DNA clones of pathogenic porcine circovirus type 2 (PCV2) and nonpathogenic PCV1 in weanling pigs.

Authors:  M Fenaux; T Opriessnig; P G Halbur; X J Meng
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Detection of a novel strain of porcine circovirus in pigs with postweaning multisystemic wasting syndrome.

Authors:  I Morozov; T Sirinarumitr; S D Sorden; P G Halbur; M K Morgan; K J Yoon; P S Paul
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Development and validation of an ELISA using a protein encoded by ORF2 antigenic domain of porcine circovirus type 2.

Authors:  Shi-Qi Sun; Hui-Chen Guo; De-Hui Sun; Shuang-Hui Yin; You-Jun Shang; Xue-Peng Cai; Xiang-Tao Liu
Journal:  Virol J       Date:  2010-10-19       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.